BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Optimisation of a recombinant vaccine to control parasitic nematod
 es - Dr Alasdair Nisbet\, Moredun Research Institute
DTSTART:20180509T150000Z
DTEND:20180509T160000Z
UID:TALK102304@talks.cam.ac.uk
CONTACT:Fiona Roby
DESCRIPTION:Teladorsagiosis is a major production-limiting disease in smal
 l ruminants in temperate regions throughout the world and is currently con
 trolled using anthelmintics\; however\, resistance to Class I to III produ
 cts is rife and multi-class resistant isolates have been reported.   As an
  alternative method of control\, we have developed a recombinant vaccine f
 or Teladorsagia circumcincta which\, when administered to 6-7 month-old la
 mbs in two separate trials\, significantly reduced nematode egg output.  D
 uring the period of peak worm egg shedding\, vaccinated lambs shed 92% and
  73% fewer eggs than did adjuvant only recipient lambs\, respectively.   A
 s well as protecting older lambs\, one of the key interventions in the man
 agement of the disease is the prevention of pasture contamination with T. 
 circumcincta eggs by ewes during the periparturient relaxation in immunity
  (PPRI) which occurs in the period around lambing. We have immunised 3-4 y
 ear old twin-bearing ewes with a T. circumcincta recombinant subunit vacci
 ne and measured the impact that vaccination has on their immune responses 
 and shedding of parasite eggs during a continuous T. circumcincta challeng
 e period spanning late gestation and lactation. In ewes which displayed a 
 clear periparturient relaxation in immunity\, vaccination resulted in a re
 duction in mean cumulative faecal egg count compared to control (immunised
  with adjuvant only) ewes suggesting that\, by immunising ewes to reduce s
 usceptibility to infection during the PPRI\, an important route of transmi
 ssion of T. circumcincta could be blocked. To optimise the recombinant vac
 cine further and exploit it commercially we have developed a strategy to u
 nderstand the nature of the vaccine-induced immunity and to tailor the key
  vaccine components accordingly. This approach and it’s outcomes will be
  presented.
LOCATION:Lecture Theatre 2\, Department of Veterinary Medicine
END:VEVENT
END:VCALENDAR